In the R&D system of cell and gene therapy (CGT), the quality control of raw materials, starting materials and excipients serves as the cornerstone of the entire industry. Unlike small-molecule drugs or monoclonal antibody products, CGT therapeutics exhibit extremely high sensitivity to raw materials. Any material variations overlooked in the early development stage may trigger cascading effects during process scaling, ultimately compromising the safety and efficacy of final medicinal products.
This article comprehensively analyzes the core control strategies for CGT raw materials from the dimensions of technical logic, risk assessment and regulatory requirements.
Microscopic Complexity: Taking Plasmid DNA as an Example
The complexity of raw materials far exceeds basic physical and chemical indicators. As the core starting material for viral vector manufacturing, plasmid DNA possesses highly nuanced quality attributes:
Dramatic impacts of microscopic discrepancies: Minor variations of merely one or two nucleotides in the plasmid DNA sequence, or changes in topological structures such as the proportion of supercoiled DNA, can profoundly alter the potency, purity and even safety profiles of viral vectors.
Gaps in analytical characterization: Conventional sequencing and general physicochemical analysis methods often fail to fully capture all critical quality attributes (CQAs) of plasmids. Such “analytical gaps” hinder the evaluation of batch-to-batch consistency and pose substantial challenges in meeting rigorous comparability review requirements for regulatory submissions.
Technical Insight: Raw materials are not standardized universal components. Developers must establish in-depth characterization methodologies beyond supplier certificates of analysis (CoA) to achieve precise control over the microscopic properties of critical materials.
Risk Grading and Material Selection Strategies
In CGT process development, material selection directly determines subsequent process robustness and regulatory compliance.
Biological vs. chemically defined sources: Serum, human-derived and animal-derived components remain major risk factors due to their inherent compositional complexity and inherent batch-to-batch variability.
Trend toward recombinant alternatives: Priority should be given to chemically defined or recombinant substitutes. Despite higher upfront procurement costs, these alternatives effectively reduce process variability, streamline regulatory communications, and minimize large-scale validation efforts caused by material changes.
Balance between cost and quality: Cost-cutting shortcuts adopted at the raw material stage, such as adopting low-grade reagents, invariably lead to exponential increases in R&D costs in later stages.
Regulatory Shift: From Compliance Certification to Risk-Based Control
Global regulatory authorities are undergoing a profound shift in their oversight priorities for CGT raw materials:
In-depth comprehension of material functions and impacts: Regulators require applicants to provide not only qualification certificates but also clear documentation of each material’s functional role in manufacturing processes, its specific impacts on product CQAs, and potential variation ranges.
Phased management framework: Early-stage development: Focuses on material safety, preliminary supplier qualification and core hazard identification. Non-clinical grade materials are conditionally acceptable with complete source documentation. Late-stage clinical and commercialization: Sophisticated analytical methods, stringent supplier audit systems and robust risk mitigation measures are mandatory. All materials shall comply with GMP-grade specifications.
Benchmarking against technical standards: USP <1043>, the guidance for excipients used in cell, gene and tissue-engineered products, has evolved into a de facto industry benchmark, guiding stakeholders to conduct risk classification based on material contact levels and biological activity.
Technical Evaluation Criteria for Supplier Qualification
Supplier selection shall follow a comprehensive evaluation framework covering technical compatibility, quality management and supply stability:
Technical transparency: Reliable suppliers shall fully disclose critical control points and inherent limitations of their manufacturing processes. Key information such as the use of antibiotics or animal-derived additives during production is essential for downstream residual testing and risk control.
Robust change control capabilities: Suppliers shall implement a proactive notification mechanism for any modifications to manufacturing processes, production facilities or self-sourced raw materials, enabling timely risk assessment and remedial actions for downstream users.
Collaborative testing alignment: Developers shall align analytical methodologies, residue detection indicators and testing standards with suppliers at an early stage. Divergent testing protocols for identical quality parameters frequently trigger batch acceptance disputes and supply disruptions.
Characterization Challenges of Particulate Matter and Complex Attributes
Visible and sub-visible particulate impurities in raw materials have drawn intensified regulatory scrutiny across the CGT sector.
Such particulates can directly disrupt cell growth kinetics and viral vector production efficiency. For instance, microscale particles in excipients may induce cellular stress responses and trigger unforeseen metabolic byproducts, undermining the purity of final products. Additionally, strict characterization of purity, specific activity and endotoxin levels is indispensable for active materials including cytokines and growth factors. This necessitates the adoption of advanced characterization technologies, such as sub-visible particle counting and targeted residue quantification.
Technical Expansion: Establishing a Full-Cycle Knowledge Chain from Starting Materials to Final Products
To achieve cost reduction and efficiency enhancement, biotech enterprises must build a holistic full-lifecycle material management system:
Establishment of in-house material attribute databases: Beyond supplier-provided specifications, multi-batch internal testing shall be conducted to establish baseline variability ranges for key materials.
Front-loaded early risk assessment: Conduct risk grading for critical materials at the laboratory stage to identify potential supply shortages and quality bottlenecks under commercial-scale production conditions.
Enhanced residual control and detection: Highly sensitive analytical methods must be developed to verify the removal efficiency of process additives (e.g., nucleases, detergents) that are introduced during manufacturing and required to be eliminated in final products.
Conclusion
Raw materials represent not only the starting point of production processes but also the decisive factor for the success or failure of CGT product development and commercialization. Through in-depth understanding of material complexity, alignment with stringent global regulatory standards, and systematic implementation of risk-based quality control strategies, developers can secure process stability amid inherent R&D uncertainties. Every rigorous quality control measure invested at the raw material stage lays a solid foundation for consistent process performance and sustainable product development in the long run.
